Canton Strategic (CNTN) vs Precision BioSciences (DTIL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Precision BioSciences (DTIL) has outperformed Canton Strategic (CNTN) over the past year, gaining 12.8% versus a loss of 34.6%. Precision BioSciences is the larger company by market cap ($177.5 million vs $165.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTN | DTIL |
|---|---|---|
| Share price | $2.08 | $6.43 |
| Market cap | $165.74M | $177.48M |
| 1-day change | -7.96% | +2.88% |
| YTD return | -31.35% | +54.57% |
| 1-year return | -34.59% | +12.81% |
| 5-year return | — | -97.87% |
| EPS (TTM) | $-0.10 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.89 | $9.62 |
| 52-week low | $1.75 | $3.53 |
| Distance from 52-week high | -69.81% | -33.16% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +357.23% |
| Average volume | 751.76K | 293.42K |
| Shares outstanding | 79.68M | 27.60M |
| Employees | 12 | 67 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DTIL has outperformed CNTN by 47.4 percentage points over the past year.
- The two companies sit in different sectors: Canton Strategic in Healthcare and Precision BioSciences in Health Care.
About Canton Strategic
CNTN stock →Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States.
Healthcare · Biotechnology · 12 employees
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 67 employees
CNTN vs DTIL FAQ
Which is bigger, Canton Strategic or Precision BioSciences?
Precision BioSciences (DTIL) is larger, with a market capitalization of $177.48M compared with $165.74M for Canton Strategic (CNTN).
Which stock has performed better over the past year, CNTN or DTIL?
DTIL returned +12.81% over the past 12 months, compared with -34.59% for CNTN (price return, excluding dividends). Past performance does not predict future results.
Are Canton Strategic and Precision BioSciences in the same industry?
No. Canton Strategic is in the Healthcare sector, while Precision BioSciences is in Health Care.